503 filings
Page 20 of 26
6-K
oltau54 ie572z
19 Oct 20
Current report (foreign)
7:37am
6-K
zqx hm32nxx1vgismd
13 Oct 20
Current report (foreign)
4:04pm
6-K
s6d5rt85n afqn
7 Oct 20
Current report (foreign)
7:50am
6-K
1v808a le4mfoi5w
1 Oct 20
Current report (foreign)
6:20am
6-K
oep 7j0fgkc
30 Sep 20
Current report (foreign)
11:00am
6-K
aapqvah5amcyjt uis
18 Sep 20
MorphoSys and I-Mab Announce FDA Clearance of IND Application
8:18am
6-K
qxghzadjtrs4g1
18 Sep 20
MorphoSys and Incyte to Host Investor Event to Discuss the Unmet
8:12am
6-K
je97 lp9578d
25 Aug 20
Current report (foreign)
8:11am
6-K
bmm8tjn5rkv
7 Aug 20
MorphoSys Reports Second Quarter and First Half
12:37pm
6-K
dzz8twskjd7keuz
5 Aug 20
Half-Year Report January – June 2020
4:18pm
6-K
h8gt 1c5t
3 Aug 20
Current report (foreign)
1:10pm
6-K
payy9t9lghd5yc
15 Jul 20
MorphoSys’s Licensee Janssen Announces Approval of Tremfya® (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
11:17am
6-K
89mhlr1ze2h0 c8
28 May 20
MorphoSys AG Reports Outcome of Annual General Meeting 2020
8:04am
6-K
3n1zh7tn
22 May 20
MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab
6:24am
6-K
a9d1lxrfvqb5 9m8o
22 May 20
MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meetings
6:18am
6-K
lhk60
15 May 20
MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL
10:19am
6-K
u13i1j pooj8
8 May 20
MorphoSys Reports First Quarter 2020 Results
6:25am
6-K
f6fpbq
6 May 20
First Quarter Interim Statement
4:19pm
6-K
awue51tpfrc7p6uacylb
28 Apr 20
MorphoSys andI-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
11:21am
6-K
07dbp
24 Apr 20
MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
11:02am